METHOD FOR DETECTING AVAILABILITY, SEVERITY, RISK AND POSITION FOR RECIDIENTS, AND ALSO TREATMENT AND REACTION TO TREATMENT OF URINARY INFLAMMATION AND KITS FOR ITS DESCRIPTION
1. A method for detecting inflammation of the urinary tract in a patient, comprising: a) providing a sample from the patient； and b) detecting in said sample expression of at least one of the biomarkers selected from the group consisting of IL-33, IL-13, IL-10 and eosinophilic peroxidase. 2. A method according to claim 1, comprising detecting the presence of mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase. 3. The method of claim 2, comprising reacting said mRNA for IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase with a nucleic acid probe complementary to said mRNA for IL-33 and / or IL-13, and / or IL-10 and / or eosinophilic peroxidase. 4. A method according to claim 1, comprising detecting the presence of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides. The method of claim 4, comprising reacting said IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptides with an antibody specific for said IL-33 and / or IL-13 and / or IL -10 and / or eosinophilic peroxidase and detecting binding of the indicated antibody to the indicated IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase polypeptide. 6. The method of claim 1, wherein the test person is a human. The method of claim 1, wherein the sample includes urine, blood, and / or cells or tissue of the bladder. A method of treating an inflammation of the urinary tract detected in accordance with the method of claim 1, comprising: a) providing a sample from the subject； b) detecting the expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase in the specified sample； c) based on the indicated expression of IL-33 and / or IL-13 and / or IL-10 and / or eosinophilic peroxidase, suppression of inflammation with1. Способ обнаружения воспаления мочевыводящих путей у пациента, содержащий: а) обеспечение образца от пациента； и б) обнаружение в указанном образце экспрессии по меньшей
